Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.55 |
| ▸ | STS | P08842 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22773317 | 1.00 | MMP13 (0.55) | MMP13STSKMT2ALIMK2KDM4E | |
| SCHEMBL22773318 | 1.00 | MMP13 (0.55) | MMP13STSKMT2ALIMK2KDM4E | |
| SCHEMBL22491579 | 0.91 | KMT2A (0.53) | MMP13STSKMT2ALIMK2SFRP1 | |
| SCHEMBL23211970 | 0.91 | STS (0.52) | MMP13STSKMT2ALIMK2MEN1 | |
| SCHEMBL22491580 | 0.91 | KMT2A (0.53) | MMP13STSKMT2ALIMK2SFRP1 | |
| SCHEMBL23211969 | 0.91 | STS (0.52) | MMP13STSKMT2ALIMK2MEN1 | |
| SCHEMBL23211953 | 0.89 | STS (0.48) | MMP13STSKMT2ASFRP1MEN1 | |
| SCHEMBL23211955 | 0.89 | STS (0.48) | MMP13STSKMT2ASFRP1MEN1 | |
| SCHEMBL30149804 | 0.89 | STS (0.48) | MMP13STSKMT2ASFRP1MEN1 | |
| SCHEMBL23211799 | 0.87 | POLB (0.45) | KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | MMP13 4059/4885STS 1021/4885KMT2A 2194/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | MMP13 4059/4885STS 1021/4885KMT2A 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.